Alurar rigakafin COVID-19 na Pfizer shine farkon wanda FDA ta amince dashi

Wadatacce

• Bita don

Hukumar Abinci da Magunguna ta Amurka ta nuna alamar babba Babban ci gaba a ranar Litinin ta hanyar ba da izinin Pfizer-BioNTech COVID-19 allurar rigakafin ga mutane masu shekaru 16 ko fiye.Alurar rigakafin Pfizer-BioNTech mai kashi biyu, wacce ta sami koren haske don izinin amfani da gaggawa ta FDA a watan Disambar da ya gabata, yanzu shine rigakafin coronavirus na farko da ya sami cikakkiyar amincewa daga kungiyar.

"Yayin da wannan da sauran alluran rigakafin suka cika ƙaƙƙarfan ƙa'idodin FDA, ƙa'idodin kimiyya don ba da izinin amfani da gaggawa, a matsayin allurar COVID-19 ta farko da FDA ta amince da shi, jama'a na iya kasancewa da kwarin gwiwa cewa wannan allurar ta cika manyan ƙa'idodi don aminci, tasiri, da masana'antu. ingancin da FDA ke buƙatar samfurin da aka amince da shi, "in ji Janet Woodcock, MD, mukaddashin kwamishina FDA, a cikin wata sanarwa ranar Litinin. "Yayin da miliyoyin mutane sun rigaya sun karɓi rigakafin COVID-19 cikin aminci, mun fahimci cewa ga wasu, amincewar FDA na maganin rigakafi na iya haifar da ƙarin kwarin gwiwa don yin rigakafin. Babban ci gaba na yau ya sanya mu mataki ɗaya kusa da canza yanayin wannan annoba Amurka " (Mai Alaƙa: Ta yaya Alurar COVID-19 ke Inganci)

A halin yanzu, sama da Amurkawa miliyan 170 sun sami cikakkiyar allurar rigakafin COVID-19, bisa ga bayanan kwanan nan daga Cibiyoyin Kula da Cututtuka da Cututtuka, wanda ya kai kashi 51.5 na yawan jama'a. Daga cikin waɗannan mutane miliyan 170, sama da miliyan 92 sun karɓi allurar Pfizer-BioNTech mai kashi biyu, a cewar CDC.

Yayinda sama da mutane miliyan 64 a Amurka aka cika su da allurar Moderna mai kashi biyu, a cewar bayanan CDC na baya-bayan nan, masu kula da har yanzu suna kan aiwatar da bitar aikace-aikacen kamfanin don cikakken yarda da allurar COVID-19, Jaridar New York Times ya ruwaito Litinin. A karkashin EUA-wanda kuma ya shafi allurar Johnson & Johnson guda ɗaya-FDA ta ba da damar amfani da samfuran magunguna da ba a amince da su ba yayin bala'in lafiyar jama'a (kamar cutar ta COVID-19) don magance ko hana cututtukan da ke barazanar rayuwa.

Tare da lamuran COVID-19 na ci gaba da ƙaruwa a cikin ƙasa baki ɗaya saboda tsananin bambancin Delta, amincewar FDA na allurar Pfizer-BioNTech na iya haifar da buƙatun rigakafi tsakanin kwalejoji, ƙungiyoyi, da asibitoci, a cewar Jaridar New York Times. Wasu garuruwa, gami da New York, tuni suna buƙatar ma'aikata da masu ba da agaji don nuna tabbacin allurar rigakafi don shiga cikin ayyukan cikin gida da yawa, gami da nishaɗi da cin abinci.

Masking da yin nesantawar jama'a suna da mahimmanci a cikin yaƙi da COVID-19, amma alluran rigakafi sun kasance mafi kyawun fa'idar kare kai da sauran mutane. A sakamakon babban labari na ranar Litinin daga FDA, watakila wannan zai sanya kwarin gwiwa na rigakafin rigakafi ga waɗanda ke da yuwuwar yin taka tsantsan game da karɓar kashi.

Bayanai a cikin wannan labarin daidai ne har zuwa lokacin da ake bugawa. Yayin da sabuntawa game da coronavirus COVID-19 ke ci gaba da haɓaka, yana yiwuwa wasu bayanai da shawarwari a cikin wannan labarin sun canza tun farkon bugawa. Muna ƙarfafa ku da ku bincika akai-akai tare da albarkatu kamar CDC, WHO, da sashin kula da lafiyar jama'a na gida don ƙarin sabbin bayanai da shawarwari.

Bita don